Prognostic Markers in Prostate Cancer
Author Information
Author(s): Calvert N W, Morgan A B, Catto J W F, Hamdy F C, Akehurst R L, Mouncey P, Paisley S
Primary Institution: School of Health and Related Research, University of Sheffield
Hypothesis
Can the addition of DNA-ploidy as a prognostic marker improve the cost-effectiveness of treatment for prostate cancer?
Conclusion
Using DNA-ploidy as a prognostic marker can lead to more cost-effective treatment decisions for prostate cancer.
Supporting Evidence
- The model predicts that 19% of untreated patients will progress to metastatic disease after 15 years.
- Observation is the least costly treatment policy compared to surgery for all.
- The marker-based treatment selection policy yields more quality-adjusted life years than surgery for all.
Takeaway
This study looks at how a special test can help doctors decide the best treatment for men with prostate cancer, which can save money and help patients live better.
Methodology
A decision analytic Markov model was built using evidence from published literature and local data sources.
Potential Biases
Potential biases in the assumptions regarding quality of life and treatment outcomes.
Limitations
The model relies on assumptions and lacks long-term follow-up data from randomized controlled trials.
Participant Demographics
The modelled cohort consists of 1000, 60-year-old men diagnosed with moderately differentiated prostate cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website